Eli Lilly PE Ratio 2006-2018 | LLY

Current and historical price to earnings ratio for Eli Lilly (LLY) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for Eli Lilly as of August 15, 2018 is 20.37.
Eli Lilly Annual PE Ratio
Eli Lilly Quarterly PE Ratio
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $110.019B $22.871B
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $347.436B 16.60
Pfizer (PFE) United States $242.341B 14.19
Novartis AG (NVS) Switzerland $190.356B 16.33
Merck (MRK) United States $179.189B 15.82
AbbVie (ABBV) United States $145.249B 14.19
Novo Nordisk (NVO) Denmark $118.145B 18.89
Sanofi (SNY) France $103.584B 13.11
AstraZeneca (AZN) United Kingdom $98.732B 10.86
GlaxoSmithKline (GSK) United Kingdom $98.701B 13.18
Bristol-Myers Squibb (BMY) United States $98.007B 17.74